Product Description
Mechanisms of Action: D2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Substance Abuse Unspecified
Phase 2: Healthy Volunteers|Parkinson's Disease
Phase 1: Depressive Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2015P002520 | N/A |
Completed |
Depressive Disorder, Major |
2021-03-01 |
|
| 2011-003071-11 | P2 |
Active, not recruiting |
Healthy Volunteers |
2014-01-31 |
|
| 2007-002496-14 | P2 |
Terminated |
Parkinson's Disease |
2008-03-27 |
|
| Motor Memory | N/A |
Completed |
Parkinson's Disease |
None |